Enfuvirtide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Enfuvirtide}} | {{Enfuvirtide}} | ||
'''''For patient information, click <u>[[Enfuvirtide (patient information)|here]]</u>'''''. | '''''For patient information, click <u>[[Enfuvirtide Injection (patient information)|here]]</u>'''''. | ||
{{CMG}} | {{CMG}}; {{AE}} {{SS}} | ||
==Overview== | ==Overview== | ||
Revision as of 03:48, 9 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Overview
Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
Enfuvirtide therapy costs an estimated USD$25,000 per year in the United States. Its cost and inconvenient dosing regimen are factors behind its use as a reserve, for "salvage" therapy in patients with multi-drug resistant HIV.
Category
Fusion inhibitor
US Brand Names
FUZEON®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages